BACKGROUND: The main concern with the use of the pipeline embolization device (PED) in treating cerebral aneurysms is the risk of hemorrhagic and thromboembolic complications. OBJECTIVE: To investigate if P2Y12 reaction unit (PRU) values are associated with hemorrhagic and thromboembolic complications after treatment with the PED and to find an optimal range of preprocedural PRU values. METHODS: Two hundred thirty-one patients with 248 cerebral aneurysms treated with the PED were retrospectively identified. Patients were started on dual-antiplatelet treatment at least 10 days before the intervention. PRU values were checked. Univariate and multivariate logistic regression were performed. Youden Indices were calculated to determine cutoffs for optimal PRU values. RESULTS: Mean patient age was 57 years. Mean last preprocedural PRU was 132 (range: 1-382). The combined rate of major hemorrhagic complications (4%) and major thromboembolic complications (5.6%) was 9.6%. Analysis using Youden indices suggested an optimal PRU range of 70 to 150 with higher odds of complications outside this range (P = .01, odds ratio [OR] = 3 [1.2-7.5]). PRU <60 was a significant predictor of hemorrhagic complications (P = .04, OR = 2.45 [1.01-5.9]) and PRU >240 was a significant predictor of any thromboembolic complication (P = .04, OR = 3.6 [1.04-12]) and cerebral thromboembolic complications (P = .02, OR = 4 [1.2-14]). CONCLUSION: Target preoperative PRU values should be between 60 and 240 and ideally between 70 and 150. Values below this range and above it carry higher odds of hemorrhagic and thromboembolic complications, respectively.
BACKGROUND: The main concern with the use of the pipeline embolization device (PED) in treating cerebral aneurysms is the risk of hemorrhagic and thromboembolic complications. OBJECTIVE: To investigate if P2Y12 reaction unit (PRU) values are associated with hemorrhagic and thromboembolic complications after treatment with the PED and to find an optimal range of preprocedural PRU values. METHODS: Two hundred thirty-one patients with 248 cerebral aneurysms treated with the PED were retrospectively identified. Patients were started on dual-antiplatelet treatment at least 10 days before the intervention. PRU values were checked. Univariate and multivariate logistic regression were performed. Youden Indices were calculated to determine cutoffs for optimal PRU values. RESULTS: Mean patient age was 57 years. Mean last preprocedural PRU was 132 (range: 1-382). The combined rate of major hemorrhagic complications (4%) and major thromboembolic complications (5.6%) was 9.6%. Analysis using Youden indices suggested an optimal PRU range of 70 to 150 with higher odds of complications outside this range (P = .01, odds ratio [OR] = 3 [1.2-7.5]). PRU <60 was a significant predictor of hemorrhagic complications (P = .04, OR = 2.45 [1.01-5.9]) and PRU >240 was a significant predictor of any thromboembolic complication (P = .04, OR = 3.6 [1.04-12]) and cerebral thromboembolic complications (P = .02, OR = 4 [1.2-14]). CONCLUSION: Target preoperative PRU values should be between 60 and 240 and ideally between 70 and 150. Values below this range and above it carry higher odds of hemorrhagic and thromboembolic complications, respectively.
Authors: Mary In-Ping Huang Cobb; Ali R Zomorodi; Erik F Hauck; Tony P Smith; L Fernando Gonzalez Journal: Childs Nerv Syst Date: 2016-12-12 Impact factor: 1.475
Authors: Josser E Delgado Almandoz; Yasha Kayan; Andrea Tenreiro; Adam N Wallace; Jill M Scholz; Jennifer L Fease; Anna M Milner; Maximilian Mulder; Kyle M Uittenbogaard; Oscar Tenreiro-Picón Journal: Neuroradiology Date: 2017-10-06 Impact factor: 2.804
Authors: Jodi R DeGrote; Elizabeth M Olafson; Alexander Drofa; Evgueni Kouznetzov; Michael Manchak; Nathan D Leedahl; David D Leedahl Journal: Can J Hosp Pharm Date: 2018-12-31
Authors: Pouya Entezami; Devin N Holden; Alan S Boulos; Alexandra R Paul; Nicholas C Field; Emad Nourollahzadeh; Junichi Yamamoto; John C Dalfino Journal: Interv Neuroradiol Date: 2020-07-01 Impact factor: 1.610
Authors: Axel Rosengart; Malie K Collins; Philipp Hendrix; Ryley Uber; Melissa Sartori; Abhi Jain; Jennifer Mao; Oded Goren; Clemens M Schirmer; Christoph J Griessenauer Journal: Interv Neuroradiol Date: 2021-02-04 Impact factor: 1.764